Abstract Number: 841 • ACR/ARHP Annual Meeting 2018
TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
Background/Purpose: Tumor necrosis factor-a (TNF), a potent proinflammatory cytokine, activates two receptors: TNFR1 and TNFR2. Anti-TNF biological agents neutralize TNF, thus preventing both TNFR1 and…Abstract Number: 2615 • ACR/ARHP Annual Meeting 2018
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Background/Purpose: The aim of the study was to investigate the impact of smoking on disease activity, treatment adherence and treatment response in psoriatic arthritis (PsA)…Abstract Number: 621 • ACR/ARHP Annual Meeting 2017
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…Abstract Number: 1556 • ACR/ARHP Annual Meeting 2017
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…Abstract Number: 958 • ACR/ARHP Annual Meeting 2016
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…Abstract Number: 1301 • ACR/ARHP Annual Meeting 2016
Analysis of Anatomical Sites Causing Dactylitis and Their Responsiveness to Change Under TNF-Therapy in Psoriatic Arthritis By High Resolution MRI
Background/Purpose: Results: The following sites were most commonly involved in dactylitis: collateral ligament enthesitis 11/12 (92%); extensor tendons enthesitis 5/12 (42%); flexor tenosynovitis 9/12 (75%),…Abstract Number: 1668 • ACR/ARHP Annual Meeting 2016
Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both…Abstract Number: 2883 • ACR/ARHP Annual Meeting 2015
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…Abstract Number: 1594 • ACR/ARHP Annual Meeting 2014
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…Abstract Number: 305 • ACR/ARHP Annual Meeting 2013
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…Abstract Number: 314 • ACR/ARHP Annual Meeting 2013
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…Abstract Number: 2781 • ACR/ARHP Annual Meeting 2013
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…Abstract Number: 1555 • ACR/ARHP Annual Meeting 2013
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…Abstract Number: 2582 • ACR/ARHP Annual Meeting 2012
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…Abstract Number: 2231 • ACR/ARHP Annual Meeting 2012
Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Background/Purpose: Treatment resistant psoriatic arthritis (PsA) may render a patient unwell, disabled and incapable of work with previous reports suggesting that unemployment levels among PsA…
